NPM1 and acute myeloid leukemia: Altogether, these results are in keeping with known pre-clinical or clinical data regarding these agents in NPM1-mutated AML [25–28], and highlight the relevance of a multiparametric readout for ex vivo drug screening of primary AML samples.